Sunil Singhania's Abakkus enters TTK Healthcare
Not every "new" stake is actually new — and not every profit decline stays a decline. Sunil Singhania's Abakkus shows up in TTK Healthcare Ltd's latest shareholding disclosure at a 2.07% stake, in a company whose most recent quarter looked very different from the full year before it.
CMP ₹1,050 (Sept 18, 2026 close — two trading days before this update; check the live price before acting) · Market cap ₹1,484 crore · P/E 19.4x (trailing twelve months, now incorporating the Q1 FY27 rebound) — against Mankind Pharma, a much larger listed condom/consumer-healthcare peer (owner of the market-leading Manforce brand), at 42.0x (market cap ₹95,029 crore, Sept 18, 2026 close) — TTK trades well below that, though the two aren't a clean match in scale.
What TTK Healthcare actually does — and a recent divestment
Part of the TTK Group, founded in 1928 by T.T. Krishnamachari. TTK Healthcare is a diversified consumer-health company across six segments: Animal Welfare (veterinary products), Consumer Products (Woodward's Gripe Water, EVA cosmetics, Good Home), Medical Devices (artificial heart valves, orthopaedic implants), Protective Devices (condoms under the Skore brand — the company's own description puts it as the second-largest condom manufacturer in Asia-Pacific), Foods, and a small legacy Maps & Atlases business. It has no subsidiaries — everything reported is the standalone company. On July 23, 2026 the company signed a definitive agreement to sell its Consumer Products brands EVA and Good Home to Wipro Enterprises for ₹256 crore plus GST, expected to close by September 30, 2026 — the net book value of those assets was just ₹0.70 crore as of June 30, 2026, meaning a very large gain will hit the books once the sale actually completes.
FY26 (year to March 2026) revenue rose 7% to ₹857.28 crore, but profit after tax fell 19.6% to ₹65.68 crore — driven by a segment loss in Protective Devices, plus a one-off ₹7.58 crore Labour Code charge, partly offset by a ₹3.50 crore GST refund. That FY26 weakness didn't carry into Q1 FY27: revenue grew 13.7% year-on-year to ₹257.56 crore (and 18.2% quarter-on-quarter), while profit after tax surged 63.7% year-on-year to ₹21.28 crore. The turnaround was concentrated in exactly the segment that dragged FY26 down:
Segment (Q1 FY27 vs Q1 FY26) Revenue growth Segment profit --------- Protective Devices (condoms) +37.9% Swung from -₹5.44cr to +₹6.13cr Medical Devices +16.4% ₹7.58cr (from ₹8.07cr — slight decline) Consumer Products +1.9% ₹2.84cr (from ₹1.26cr, +125%) Foods +2.6% ₹4.12cr (from ₹2.94cr, +40.1%) Animal Welfare +12.6% ₹1.15cr (from ₹2.34cr — declined)
A segment loss can reverse just as fast as it appeared Protective Devices swung from a ₹5.44 crore loss to a ₹6.13 crore profit in a single quarter, driven by recovery of previously-cancelled USAID male-contraceptive orders (₹5.45 crore) that had been written off in FY25 amid a 90-day US foreign-aid pause. That's real cash landing this quarter — but it also means the FY26 loss and the Q1 FY27 recovery are two sides of the same geopolitical-dependency coin, not evidence the underlying business has structurally changed.
The Abakkus position: not actually a fresh buy
Per shareholding-pattern trackers, Abakkus (via its Diversified Alpha Fund) first appeared as a TTK Healthcare shareholder in the September 2023 quarter at 1.13%, holding that disclosed level through September 2025. The stake fell below the 1% public-disclosure threshold by the March 2026 quarter — that only means it dropped below 1%, not that Abakkus necessarily sold down deliberately. By the June 2026 quarter, the disclosed stake had returned to 2.07% (2,93,030 shares) — a re-accumulation of a long-held position, not a new discovery of the stock. No confirmed purchase price for this specific increase was found in public sources.
What's next: a pending gain, and no formal guidance
TTK hasn't issued specific forward revenue or profit guidance in its recent filings. The one concrete near-term event is the EVA/Good Home sale to Wipro closing by September 30, 2026 — given the ₹256 crore sale price against a ₹0.70 crore net book value, this should book a substantial one-time gain in Q2 FY27 once completed, separate from and in addition to the underlying operating business. The other live risk flagged in the company's own filings is continued exposure to Labour Code changes notified in November 2025, which already forced a ₹7.58 crore exceptional charge in FY26 and could recur.
How does its valuation compare with a listed peer?
Mankind Pharma — primarily a large pharmaceutical company with a sizeable consumer-healthcare business, whose Manforce brand leads the Indian condom market with an estimated 28-30% share — trades at a P/E of roughly 42.0x (market cap ₹95,029 crore, as of Sept 18, 2026 close). TTK's 19.4x P/E (trailing twelve months, now incorporating the Q1 FY27 rebound in the earnings base) sits well below that, but Mankind isn't really a direct peer — it's a far larger, faster-growing, primarily-pharma company where consumer healthcare is one piece of a bigger business. A cheaper P/E here reflects real differences in growth, scale and business mix, not necessarily an overlooked bargain. Notably, no formal brokerage research coverage (a Motilal Oswal, ICICI Direct, HDFC Securities-style rating and target price) turned up for TTK Healthcare despite its decades-long listing history — somewhat unusual for a company this old, and a reminder that "no analyst has flagged a problem" isn't the same as "no analyst is watching."
Should you chase it?
A tracked investor's stake resurfacing above 2% is a real, disclosed fact, but the story here is a long-held position being rebuilt, not a fresh conviction call on new information. What has genuinely changed since the FY26 numbers alone would suggest: Q1 FY27 profit is up 63.7% year-on-year on a real recovery in the previously loss-making Protective Devices segment, and a substantial one-time gain is coming once the Wipro divestment closes (expected within this quarter). Both are real positives the FY26-only picture missed — but the Protective Devices recovery is tied to a US-aid-dependent order book that has already proven it can reverse just as fast the other way, and the Wipro gain is one-time, not a repeatable earnings driver. Read the Q1 FY27 results and the Wipro divestment completion notice directly before treating either the improved numbers or Abakkus's renewed stake as a standalone signal. Also note that TTK's share price has fallen from roughly ₹1,190 in mid-September to ₹1,050 by Sept 18 — check the current quote before acting either way.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- TTK Healthcare — screener.in - TTK Healthcare Q1 FY27 results outcome (NSE filing) - Mankind Pharma — screener.in